×

Acorda CEO Projects $255 Million From AMPYRA

6:45 PM ET Tue, 19 June 2012

Ron Cohen, Acorda Therapeutics president & CEO, offers insight on just how much potential his company's multiple sclerosis drug "AMPYRA" has in the pharmaceutical market.